Epoetin Alfa Therapy for Patients with Hematologic Malignancies and Mild Anemia

2003 ◽  
Vol 4 ◽  
pp. S13-S17 ◽  
Author(s):  
David J. Straus
Keyword(s):  
Hematologic Malignancies ◽  
Epoetin Alfa ◽  
Mild Anemia

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

2003 ◽  
Vol 21 (4) ◽  
pp. 169-180 ◽  
Author(s):  
Timothy J. Littlewood ◽  
Johan Nortier ◽  
Bernardo Rapoport ◽  
Marek Pawlicki ◽  
Gilbert De Wasch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hematologic Malignancies ◽  
Epoetin Alfa ◽  
Platinum Chemotherapy

Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5132-5132 ◽  
Author(s):  
M. Marinaccio ◽  
E. Mele ◽  
S. Poma ◽  
C. Cantinieri ◽  
M. Cocca ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Epoetin Alfa ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Mild Anemia

Cognitive Effects of Once Weekly (QW) Epoetin Alfa in Anemic Patients (pts) with Hematologic Malignancies Receiving Chemotherapy (CT): Interim Results of the EPOLYM Trial.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2217-2217 ◽  
Author(s):  
Christian Gisselbrecht ◽  
Hans Tesch ◽  
Eric Jourdan ◽  
Giuseppe Avvisati ◽  
Costas Tsatalas ◽  
...  
Keyword(s):  
Working Memory ◽  
Reaction Time ◽  
Cognitive Function ◽  
Cognitive Assessment ◽  
Interim Analysis ◽  
Hematologic Malignancies ◽  
Assessment System ◽  
Anxiety And Depression ◽  
Epoetin Alfa

Abstract CT-associated cognitive dysfunction, which frequently manifests as subtle changes in memory, concentration, and ability to remain focused or organized, can adversely affect cancer pts’ QOL. EPOLYM, a prospective, international, multicenter, open-label, phase IIIb trial has been conducted to investigate the efficacy, safety, and clinical outcomes, including effect on cognitive function, of epoetin alfa 40,000 IU sc QW in anemic (Hb <12 g/dL) pts with hematologic malignancies. Pts enrolled had either non-Hodgkin’s lymphoma, multiple myeloma, Hodgkin’s disease, or chronic lymphocytic leukemia, for which they were receiving or were expected to receive CT (planned N = 1,000). Dosage increases or decreases were to be made based on clinical response (target Hb, 11.5–13.0 g/dL). Cognitive function was evaluated from baseline to Week 24 (or last evaluation) using the Cognitive Drug Research Computerised Cognitive Assessment System, patient-completed, computer-scored tasks of attention (Simple Reaction Time, Choice Reaction Time, Digit Vigilance), working memory (Numeric Working Memory), and secondary memory (Immediate and Delayed Word Recognition, Picture Recognition). To further characterize the data, task scores were variously summed to provide 4 factor scores (and aspects of cognitive function measured): Power of Attention (concentration intensity), Continuity of Attention (ability to sustain concentration), Quality of Memory (amount of information that can be stored and successfully retrieved in working and long-term memory), and Speed of Memory (speed in ability to recognize information previously presented or held in working memory). Changes from baseline in Hb levels and transfusion requirements were determined and QOL was assessed using the Functional Assessment of Cancer Therapy-Anemia Subscale and the Linear Analog Scale Assessment. Because of the apparent relationship between affect and cognition, anxiety and depression were evaluated at the time of cognitive assessment using the Hospital Anxiety and Depression Scale (HADS). Transfusion, QOL, and HADS results are not considered here. The cognitive data for 568 pts who had completed up to 24 weeks of therapy were examined in an interim analysis. Results showed that Power of Attention was slightly impaired and Continuity of Attention was slightly improved over the course of the study; however, these effects were small and unlikely to have everyday behavioral significance. Greater changes were observed in regard to memory. Mean Speed of Memory was decreased 358.9 msec by Week 24, representing an 8% improvement from baseline. Also, improvement was noted in Quality of Memory, with the score for this factor increased by 0.0899 at Week 24 from a baseline value of 2.895. The improvement in cognitive function was associated with an increase in Hb from 10.5 g/dL at baseline to about 12 g/dL beginning at Weeks 8 to 12 and sustained for up to 24 weeks. Results of this interim analysis suggest improvement in several aspects of cognitive function associated with increased Hb levels in anemic CT pts with hematologic malignancies. These results will have to be confirmed by findings based on the full study cohort.

Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5132-5132
Author(s):  
M. Marinaccio ◽  
E. Mele ◽  
S. Poma ◽  
C. Cantinieri ◽  
M. Cocca ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Epoetin Alfa ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Mild Anemia

Author response for "Should we screen patients with hematologic malignancies for COVID ‐19?"

2020 ◽  
Author(s):  
Elie Rassy ◽  
Rita‐Maria Khoury‐Abboud ◽  
Nathalie Ibrahim ◽  
Tarek Assi ◽  
Bachar Samra ◽  
...  
Keyword(s):  
Hematologic Malignancies ◽  
Author Response
Sign in / Sign up

Export Citation Format

Share Document